Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Farmers Insurance
Medtronic
QuintilesIMS
Harvard Business School
AstraZeneca
McKesson
Julphar
Deloitte

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEPO-TESTOSTERONE

« Back to Dashboard

Clinical Trials for Depo-testosterone

Trial ID Title Status Sponsor Phase Summary
NCT00000175 The Effects of Sex Hormones on Cognition and Mood in Older Adults Terminated National Institute on Aging (NIA) N/A This study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. During the nine month long study, men will take testosterone for three months and women will take estrogen for three months. At four points during the study (once every three months), participants will complete a test battery and have blood drawn.
NCT00000177 Estrogen Hormone Protocol Completed National Institute on Aging (NIA) Phase 3 Estrogen is a hormone that is dominant in the female reproductive system. In women, most estrogen is produced by the ovaries. Men produce estrogen by converting testosterone into estrogen. Because this hormone also has many beneficial effects on brain cells, it currently is being studied as a treatment for Alzheimer's disease. The enzyme that forms the neurotransmitter acetylcholine is promoted in the presence of estrogen. Several very small clinical studies have demonstrated improvement in cognitive function and mood measures in women with Alzheimer's disease who take estrogen.
NCT00000854 A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 The purpose of this study is to see if giving nandrolone decanoate (a hormonal drug) will cause weight gain in HIV-positive women who have HIV-associated weight loss (wasting). Wasting has become an AIDS-defining condition. In the past, most studies that examined wasting treatments were limited to men. However, it appears that wasting in HIV-positive men is linked to levels of testosterone (a hormone which affects men's bodies more than women's). This study has been designed for women only, in order to best treat wasting in HIV-positive women.
NCT00001079 A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 To test the hypothesis that the predominant accrual of fat rather than lean body mass (LBM) that occurs during treatment of HIV-associated wasting with megestrol acetate may be improved by treatment with megestrol acetate and testosterone enanthate in combination. Body wasting is an increasingly frequent AIDS-defining condition in individuals infected with HIV. Increasing caloric intake fails to consistently restore lean tissue patients with HIV associated weight loss. Megestrol acetate has been shown to stimulate appetite and weight gain in subjects with cancer and in those with HIV associated weight loss. However, the weight gained during treatment with megestrol acetate was predominantly or exclusively fat. An important factor is the preferential increase in body fat seen in both of these studies may have been due to hypogonadism that occurs as a result of treatment with megestrol acetate, a progestational agent. Hypogonadism is associated with an increase in body fat and a decrease in LBM. Concomitant testosterone replacement should substantially increase the amount of LBM accrued during megestrol acetate therapy. This study will determine whether anabolic potential can be realized when caloric intake is increased in the absence of concomitant hypogonadism.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Depo-testosterone

Condition Name

Condition Name for Depo-testosterone
Intervention Trials
Prostate Cancer 157
Hypogonadism 122
Polycystic Ovary Syndrome 43
Obesity 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Depo-testosterone
Intervention Trials
Prostatic Neoplasms 223
Hypogonadism 182
Polycystic Ovary Syndrome 51
Syndrome 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Depo-testosterone

Trials by Country

Trials by Country for Depo-testosterone
Location Trials
Canada 107
United Kingdom 53
Germany 41
Australia 34
Brazil 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Depo-testosterone
Location Trials
California 137
Texas 135
New York 108
Massachusetts 96
Florida 88
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Depo-testosterone

Clinical Trial Phase

Clinical Trial Phase for Depo-testosterone
Clinical Trial Phase Trials
Phase 4 124
Phase 3 144
Phase 2/Phase 3 30
[disabled in preview] 268
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Depo-testosterone
Clinical Trial Phase Trials
Completed 395
Recruiting 144
Not yet recruiting 78
[disabled in preview] 61
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Depo-testosterone

Sponsor Name

Sponsor Name for Depo-testosterone
Sponsor Trials
National Cancer Institute (NCI) 57
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 43
University of Washington 35
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Depo-testosterone
Sponsor Trials
Other 810
Industry 353
NIH 173
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
AstraZeneca
Healthtrust
Accenture
QuintilesIMS
Moodys
Farmers Insurance
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.